Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

Q1 2025 Management View CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, ...

Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was $15 million for the first quarter ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Title: Patient insights expand understanding of APDS Presenting Author: Kristie Cline, MBA, Pharming Healthcare, Inc., Warren, NJ, USA Session Type: Poster Session Date/Time: Saturday, May 3, 2025, ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

Cogent Biosciences (COGT) announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer ...

Huo Xue Tong Luo Capsule (HXTL) has been clinically used to treat osteonecrosis of the femoral head, osteoporosis, and other bone and joint diseases with promising effects.

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The report provides product descriptions, patent details, and ...

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...